Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (FLAG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01266213

Recruitment Status : Unknown

Verified April 2017 by Young-Hyuck Im, Samsung Medical Center.
Recruitment status was: Active, not recruiting

First Posted : December 24, 2010

Last Update Posted : May 1, 2017

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Asan Medical Center

Seoul National University Hospital

Severance Hospital

Ulsan University Hospital

Kosin University Gospel Hospital

Korea University Guro Hospital

Korea University Anam Hospital

Information provided by (Responsible Party):

Young-Hyuck Im, Samsung Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 2018
Estimated Study Completion Date :	December 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH, Park YH, Kim TY, Kim SB, Lee KS, Kim GM, Kim SH, Kim S, Ahn JS, Lee KH, Ahn JH, Park IH, Im YH; breast cancer committee of Korean Cancer Study Group (KCSG). Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). Eur J Cancer. 2018 Nov;103:127-136. doi: 10.1016/j.ejca.2018.08.004. Epub 2018 Sep 14.

To Top